Detalles de la búsqueda
1.
Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study.
Eur J Nucl Med Mol Imaging
; 48(4): 1103-1115, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32995944
2.
Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.
Br J Clin Pharmacol
; 84(10): 2422-2432, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29959802
3.
Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease.
BMC Med Inform Decis Mak
; 18(1): 138, 2018 12 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-30572891
4.
Prospective flutemetamol positron emission tomography and histopathology in normal pressure hydrocephalus.
Neurodegener Dis
; 13(4): 237-45, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24296542
5.
Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes.
J Neurol Neurosurg Psychiatry
; 84(11): 1288-95, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23486993
6.
Changes in clinical management and diagnosis following DaTscan SPECT imaging in patients with clinically uncertain parkinsonian syndromes: a 12-week follow-up study.
Neurodegener Dis
; 11(1): 22-32, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-22571977
7.
[(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid ß detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
Acta Neuropathol
; 124(6): 833-45, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23053137
8.
Impact of DaTscan SPECT imaging on clinical management, diagnosis, confidence of diagnosis, quality of life, health resource use and safety in patients with clinically uncertain parkinsonian syndromes: a prospective 1-year follow-up of an open-label controlled study.
J Neurol Neurosurg Psychiatry
; 83(6): 620-8, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22492213
9.
Prerequisites to launch neuroprotective trials in Parkinson's disease: an industry perspective.
Mov Disord
; 27(5): 651-5, 2012 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22508283
10.
Improved characterization of BOLD responses for evoked sensory stimuli.
Neuroimage
; 49(3): 2275-86, 2010 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19854280
11.
Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR.
Neuroimage
; 52(4): 1505-13, 2010 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20406692
12.
Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.
J Huntingtons Dis
; 9(2): 173-184, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32508327
13.
Pain fMRI in rat cervical spinal cord: an echo planar imaging evaluation of sensitivity of BOLD and blood volume-weighted fMRI.
Neuroimage
; 44(2): 349-62, 2009 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18835453
14.
Dopamine transporter imaging with [123I]FP-CIT (DaTSCAN) in Parkinson's disease with depressive symptoms: a biological marker for causal relationships?
J Neurol Neurosurg Psychiatry
; 85(2): 130-1, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23833268
15.
Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor Devices.
Digit Biomark
; 3(3): 103-115, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-32095771
16.
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.
Lancet Neurol
; 18(2): 165-176, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30563778
17.
An in vivo [18F]MK-9470 microPET study of type 1 cannabinoid receptor binding in Wistar rats after chronic administration of valproate and levetiracetam.
Neuropharmacology
; 54(7): 1103-6, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18423778
18.
Whole-body biodistribution and radiation dosimetry of the human cannabinoid type-1 receptor ligand 18F-MK-9470 in healthy subjects.
J Nucl Med
; 49(3): 439-45, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18287275
19.
Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.
J Huntingtons Dis
; 6(3): 189-199, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28826192
20.
Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.
JAMA Neurol
; 72(3): 287-94, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25622185